Edition:
United States

Heat Biologics Inc (HTBX.OQ)

HTBX.OQ on NASDAQ Stock Exchange Capital Market

2.48USD
20 Jun 2018
Change (% chg)

$0.12 (+5.08%)
Prev Close
$2.36
Open
$2.36
Day's High
$2.49
Day's Low
$2.34
Volume
123,063
Avg. Vol
239,643
52-wk High
$7.85
52-wk Low
$1.09

Chart for

About

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combinatio... (more)
No analyst recommendations are available for .

Overall

Beta: 0.97
Market Cap(Mil.): $48.69
Shares Outstanding(Mil.): 20.81
Dividend: --
Yield (%): --

Financials

  HTBX.OQ Industry Sector
P/E (TTM): -- 235.76 33.88
EPS (TTM): -4.31 -- --
ROI: -172.54 -5.45 13.21
ROE: -204.56 -6.94 15.18

BRIEF-Heat Biologics Inc - QTRLY Loss Per Share $0.75

* HEAT BIOLOGICS INC - QTRLY LOSS PER SHARE $0.75 Source text: (https://bit.ly/2rHWu1b) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

May 15 2018

BRIEF-Heat Biologics Files For Offering Of Up To $15 Mln Of Its Common Stock

* FILES FOR OFFERING OF UP TO $15 MILLION OF ITS COMMON STOCK - SEC FILING Source text for Eikon: (http://bit.ly/2GFwyfW) Further company coverage:

Mar 30 2018

BRIEF-Heat Biologics Reports Data From Phase 2 Trial Of HS-410 Combined With Bacillus Calmette-Guérin For Treating Non-Muscle Invasive Bladder Cancer

* HEAT BIOLOGICS - REPORTS 2 YEAR DATA FROM PHASE 2 TRIAL OF HS-410 COMBINED WITH BACILLUS CALMETTE-GUÉRIN FOR TREATING NON-MUSCLE INVASIVE BLADDER CANCER

Mar 26 2018

BRIEF-Heat Biologics Files Prospectus Supplement Related To Offering Of Up To $1.3 Million Shares Of Co's Common Stock

* HEAT BIOLOGICS INC FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING OF UP TO $1.3 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING‍​ Source text (http://bit.ly/2G2V1vx) Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 16 2018

BRIEF-Heat Biologics - Interim Results From Phase 2 Study Investigating HS-110 In Combination With Anti-PD-1

* HEAT BIOLOGICS - INTERIM RESULTS FROM PHASE 2 STUDY INVESTIGATING HS-110 IN COMBINATION WITH BRISTOL-MYERS'S ANTI-PD-1 CHECKPOINT INHIBITOR, NIVOLUMAB

Feb 28 2018

BRIEF-Heat Biologics Gets Recommendation To Continue Patient Enrollment Of Ongoing Phase 2 Clinical Trial

* SAYS GOT INDEPENDENT DMC RECOMMENDATION TO CONTINUE PATIENT ENROLLMENT OF ONGOING PHASE 2 CLINICAL TRIAL FOR HS-110 AND NIVOLUMAB​ Source text: (http://bit.ly/2BG2kXt) Further company coverage:

Feb 20 2018

Earnings vs. Estimates